Introduction
Angiogenesis has a significant role in the pathogenesis of a wide variety of diseases, including cancer. The vascular endothelial growth factor (VEGF) pathway has been evaluated extensively, owing to its critical role in angiogenesis. The major mediator of tumor angiogenesis is VEGF-A, commonly referred to as VEGF, which activates the VEGF receptor-2. [1] [2] [3] [4] [5] Bevacizumab is a humanized monoclonal antibody raised against VEGF, able to target and inhibit all major isoforms. In patients with metastatic colorectal cancer, addition of bevacizumab to chemotherapy improves the efficacy over chemotherapy alone, in both firstand second-line settings. [6] [7] [8] However, a substantial proportion of patients receiving bevacizumab will not respond. Moreover, although treatment with bevacizumab is generally well-tolerated, a small percentage of patients will develop serious, potentially life-threatening toxicities. Therefore, identification of patients who might benefit from bevacizumab treatment is essential in the management of cancer. Retrospective analyses have been conducted investigating molecular, biological and genetic markers for bevacizumab efficacy.
The level of circulating endothelial cells may reflect the angiogenic turnover and may be of predictive importance in patients receiving bevacizumab treatment. 9 Moreover, the development of hypertension during bevacizumab therapy has been proposed as a possible biological indicator of bevacizumab activity. 10, 11 Genetic variability may also serve as a predictive biomarker for anti-VEGF agents. However, accumulating data suggest a predictive value for a number of factors, but currently, no definitive biomarkers have been identified that can reliably predict benefit from bevacizumab. Ongoing clinical studies include molecular analyses in an attempt to reveal predictive markers.
In the present study, we evaluated the association of VEGF genotypes with efficacy of irinotecan-based chemotherapy combined with bevacizumab, in a series of patients with metastatic colorectal cancer. Patients received the abovementioned regimen as first-line treatment, within the context of a randomized phase-III clinical trial.
Materials and methods

Samples
Blood samples were prospectively collected from patients who were part of the Hellenic Cooperative Oncology Group (HeCOG) 6A/05 trial population. Owing to logistical and organizational barriers, collection of blood samples was possible in 221 out of 302 patients randomized in this prospective clinical trial. The purpose of the HE6A/05 study was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer. The clinical protocol was approved by the institutional review boards of the participating institutions and by the National Organization for Medicines. The trial was also registered with the Australian New Zealand Clinical Trials Registry (ACTRN12610000270011). All patients gave written informed consent before study entry. The translational research protocol was approved by the Bioethics Committee of the Aristotle University of Thessaloniki. All patients participating in the present study gave a separate written informed consent for research use of their biological material.
Patients previously untreated for metastatic disease were randomized in Arm A (irinotecan 240 mg/m 2 day 1, capecitabine 1000 mg/m 2 days 1-14 and bevacizumab 7.5 mg/kg day 1, every 3 weeks; XELIRI-bevacizumab) and Arm B (irinotecan 180 mg/m 2 day 1, leucovorin 200 mg/m 2 day 1, 5-fluorouracil 400 mg/m 2 bolus on day 1 followed by a 5-fluorouracil 2400 mg/m 2 46 h infusion, and bevacizumab 5 mg/kg day 1, every 2 weeks; FOLFIRI-bevacizumab).
The primary endpoint of the study was progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (RR) and toxicity. From January 2006 to January 2008, 285 eligible patients were enrolled (143 in Arm A and 142 in Arm B). Median age was 66 years (range 28-84), 171 patients (60%) were males and 186 patients (65%) had performance status ¼ 0 on the Eastern Cooperative Oncology Group (ECOG) scale. Liver involvement was recorded in 190 patients (67%), whereas 153 (54%) had only one organ involved. The results of the HE6A/05 study have been presented in ASCO 2010. 12 As shown in the flow diagram of the study (Figure 1 ), 48 out of the 221 available samples were excluded from the present analysis: 12 patients were considered ineligible; 1 patient was lost to follow-up; 9 patients never started treatment and 26 patients participating in the trial did not receive bevacizumab owing to risk factors for serious adverse events. Therefore, the analysis was performed on the remaining 173 samples (81 in the XELIRI-bevacizumab and 92 in the FOLFIRI-bevacizumab arm).
Genotyping DNA was extracted from the blood samples of the patients participating in the HE6A/05 trial. Genotyping was performed for selected single-nucleotide polymorphisms (SNPs) (VEGFÀ1154, þ 936, À634, À2578 and À1498). The selection of these established genetic polymorphisms was based on their sufficient frequency in the general population, as well as previous evidence. 10 Candidate SNPs were genotyped by real-time PCR using an MX3000p PCR cycler (Stratagene, La Jolla, CA, USA). Primers (Metabion International, Martinsried, Germany) and Taqman probes (Applied Biosystems, Foster City, CA, USA) were as described by Schneider et al., 13 for À634, þ 936, À1498 and À2578 SNPs, whereas for the À1154 SNP they were adapted as follows: Forward primer, 3 0 -CGGGCCAGGCTTCACT-5 0 ; reverse primer, 5 0 -CGGGGA CAGGCGAGC-3 0 ; G probe: 5 0 -VIC-CTCAGCCCCTCCACAC-MGB-NFQ-3 0 and A probe: 5 0 -6FAM-CCTCAGCCCTTCCA CAC-MGB-NFQ-3 0 . Reactions were performed in duplicates by using 400 nM of each primer and 150 nM of each probe by using the Precision Master Mix (PrimerDesign, Southampton, UK) and included a no template control to ensure lack of contamination. Although primers and probes are designed to be sequence-specific, the nature of this assay may theoretically incorporate false positives and false negatives, given the multitude of SNPs that may be present in the VEGF gene. The thermal profile used was one cycle of 10 14 OS was measured from the date of randomization until death from any cause and surviving patients were censored at the date of last contact. PFS was measured from the date of randomization to verified disease progression, death or last contact. In the analysis of PFS, death without prior verified progression was considered to be an event. Time to event distributions was estimated by using Kaplan-Meier curves and compared by using the log-rank test. In order to examine the prognostic significance of each polymorphism, univariate Cox regression analyses adjusted for treatment were performed in terms of OS and PFS.
Prognostic factor analyses for PFS and OS were performed by using the multivariate Cox proportional hazards model. A backward selection procedure identified a subclass of significant variables among the following: age (X60 versus o60), performance status (1 or 2 versus 0), sex (women versus men), treatment arm (FOLFIRI/bevacizumab versus XELIRI/bevacizumab), liver metastasis (yes versus no), adjuvant chemotherapy (yes versus no), primary site (rectum versus rectosigmoid versus colon), number of organs involved (1 versus 2 versus X3), stage at diagnosis (IV versus I-III), VEGFÀ1154 (AA þ GA versus GG), VEGF þ 936 (CT þ TT versus CC), VEGFÀ634 (CC þ GC versus GG), VEGFÀ2578 (CA þ CC versus AA) and VEGFÀ1498 (CT þ TT versus CC). The significant factors were kept in the model if the maximum likelihood ratio criterion had a P-value o0.10.
The design of the present study was prospective-retrospective, as described by Simon et al., 15 whereas the analysis was fully compliant with the reporting recommendations for tumor marker prognostic studies. 16 For all comparisons, the level of significance was set at a ¼ 0.05. Data were analyzed by using SPSS for windows (version 15; SPSS, Chicago, IL, USA).
Results
Basic patient and tumor characteristics are shown in Table 1 . There were no significant differences in major characteristics between patients treated with XELIRI-bevacizumab versus FOLFIRI-bevacizumab, or between the whole population of the randomized study versus the patients included in the present analysis. After a median follow-up period of 29.7 months, the median OS for the 92 patients in the FOLFIRIbevacizumab arm was 26.2 months (range 0.8-38.8), whereas the median OS for the 81 patients in the XELIRIbevacizumab arm was 20.1 months (range 0.5-31.0). The median PFS was 16.5 months (range 0.8-38.8) and 15.3 months (range 0.5-35.7), respectively. In accordance with the results of the HE6A/05 trial, there was no significant difference in OS or PFS between the two groups. 12 Moreover, no significant differences in RR were demonstrated between the two treatment arms (P ¼ 0.88).
The genotypes for the evaluated VEGF polymorphisms are shown in Table 2 and conform to expectations based on the Hardy-Weinberg equilibrium (this was true even when a few samples were excluded from the analysis owing to missing patient data as well as for samples that were excluded). Moreover, genotype frequencies were similar to those reported by Schneider et al. 10 in breast cancer patients (White population) and to the frequencies available in the SNP database of the NCBI. However, larger populations are required to be genotyped to ascertain allele frequencies. In addition, the examined genotypes were not associated with basic clinicopathological characteristics ( Table 3 ). The candidate genotypes were evaluated for associations with RR and clinical outcome (Tables 4 and 5 ). The VEGFÀ1154 GG genotype was found to be significantly more frequent in nonresponders than in patients responding to treatment (65.5 versus 39.8%, P ¼ 0.032). No other significant associations between genotypes and RR were demonstrated (Table 4) .
Patients with the VEGFÀ1154 GG genotype demonstrated a significantly worse median OS compared with those with GA (hazards ratio ¼ 1.68; 95% confidence interval: 1.10-2.57; P ¼ 0.016) or with the alternative genotypes (GA and AA) combined (hazards ratio ¼ 1.62; 95% confidence interval: 1.09-2.40; P ¼ 0.017) ( Table 5 ). Kaplan-Meier curves for the VEGFÀ1154 polymorphism in terms of OS are given in Figure 2 . There were no other significant associations between VEGF genotypes and clinical outcome. In multivariate analysis, the VEGFÀ1154 GG genotype retained its significance for OS (Table 6) .
A strong linkage disequilibrium was noted between the À2578 and À1498 SNPs, and between À1154 and À634 (D 0 ¼ 0.988, r 2 ¼ 0.942 and D 0 ¼ 1, r 2 ¼ 0.254, respectively). Therefore, haplotype analysis was conducted with these SNPs only. Haplotypes with a frequency above 5% were chosen for further analysis. These were À2578 C/À1498 T/ À1154 G/À634 C (33.8%), À2578 C/À1498 T/À1154 G/À634 G (15.5%), À2578 A/À1498 C/À1154 G/À634 G (17.1%) and À2578 A/À1498 C/À1154 A/À634 G (30.8%). Haplotype À2578 A/À1498 C/À1154 A/À634 G conferred a survival benefit compared with other haplotypes (hazards ratio ¼ 0.568; 95% confidence interval: 0.379-0.850; P ¼ 0.006). No association was noted between other haplotypes and OS or PFS.
Discussion
The VEGF gene is located on chromosome-6 at location 6p21.1 and constitutes a highly polymorphic gene. Numerous common SNPs in the promoter, 5-and 3-untranslated regions have been identified. 17 This genetic variability potentially affects the expression and function of VEGF. 18 Several studies have evaluated the effect of VEGF polymorphisms on the incidence and prognosis of diseases in which angiogenesis has a critical role. Although many of these studies have demonstrated significant associations, others have failed to show such correlations. Similarly, case-control studies investigating the VEGF polymorphisms in relation to risk, clinicopathological parameters and prognosis of colon cancer have demonstrated variable results. [19] [20] [21] [22] [23] It is possible that clarification of the functional significance of these polymorphisms is necessary in order to determine the reasons for inconsistencies The two groups were well balanced in selected patient characteristics. Moreover, there were no significant differences in major patient and tumor characteristics between the patients included in this analysis and the whole population of the randomized study (P40.05 in all cases). 
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A limited body of data suggested a potential predictive value of specific VEGF genotypes for treatment with bevacizumab. A recent study retrospectively evaluated the association of VEGF genotypes with efficacy in patients with advanced breast cancer participating in the E2100 phase-III trial. 10 Patients with VEGFÀ2578 AA and VEGFÀ1154 AA genotypes receiving bevacizumab and paclitaxel, had significantly superior median OS versus patients with alternative genotypes. Moreover, these correlations were not observed in the control arm of the study, suggesting a predictive role for the aforementioned genotypes with respect to bevacizumab efficacy. In another study, ovarian cancer patients with the VEGFÀ936 CT genotype treated with cyclophosphamide and bevacizumab had a longer median PFS compared with those with the CC and TT genotype. 25 In our study, the VEGFÀ1154 GG genotype was associated with significantly worse OS in colorectal cancer patients treated with irinotecan-based chemotherapy combined with bevacizumab. Furthermore, the VEGFÀ1154 GG genotype retained its significance for OS in the multivariate analysis. In addition, the frequency of the VEGFÀ1154 GG genotype was significantly higher among patients not responding to treatment. It is of interest that the VEGFÀ1154 GG genotype has been associated with higher VEGF production. 26 In a recent study including 89 pretreated metastatic colorectal cancer patients treated with irinotecan, gemcitabine and bevacizumab, low VEGF level-associated SNPs were correlated with a better clinical outcome in terms of time to disease progression. 27 Moreover, in the analysis conducted by Schneider et al. in breast cancer patients, the VEGFÀ2578 AA and VEGFÀ1154 AA genotypes were associated with a superior OS. These genotypes have been associated with a trend for lower VEGF expression in human breast cancer specimens. 10 Furthermore, an haplotype carrying the À2578 A and À1154 A alleles (À2578 A/À1498 C/À1154 A/À634 G) was associated with improved OS in our study. Taken together, the above findings support an association between VEGF genotypes affecting the expression levels of VEGF and clinical outcome for cancer patients receiving bevacizumabcontaining treatment. A definitive association between VEGF levels and patients' outcome has not been convincingly demonstrated thus far. In the aforementioned study, which included colorectal cancer patients, 27 significantly longer median survival times were found in patients with low baseline VEGF serum levels. Similarly, in a phase-II study, which investigated the combination of bevacizumab and vinorelbine as treatment for refractory breast cancer, lower levels of baseline plasma VEGF were associated with longer time to progression. 28 By contrast, in the analysis by Schneider et al., 10 VEGF protein expression in the primary tumor was not associated with clinical outcome in the E2100 trial. However, it is important to note that assessing the expression of VEGF in the primary tumor does not necessarily reflect plasma VEGF levels or VEGF activity at the time of metastatic spread.
In the study reported by Schneider et al., the genotype effect was related to OS only and not to PFS. The authors assumed that a possible explanation could be that the genotype effect observed in their study was a statistical artifact. However, in agreement with the above-mentioned finding, no significant associations of VEGF genotypes with PFS were demonstrated in our study. Although a definitive reason cannot be identified thus far, possible explanations, including rebound angiogenesis following discontinuation of bevacizumab in patients with high basal VEGF production, have been proposed. 18 However, in a recent study including 40 patients with metastatic colorectal cancer treated with FOLFIRI-bevacizumab, the VEGFÀ1154 GG genotype was significantly associated with shorter PFS. 29 In our study, we used germline (peripheral blood) DNA for evaluation of VEGF genotypes. Previous studies have demonstrated a concordance between germline genotypes and somatic genotypes determined in tumor samples, with respect to genes involved in angiogenesis. 30 However, cases of discordant VEGF genotypes between tumor and normal tissue have been reported recently. 31 A limitation of our study is the absence of a control arm of patients not receiving bevacizumab. Therefore, a distinction between the prognostic or predictive role of the VEGF polymorphisms in terms of survival cannot be made definitely. However, the association of the specific genotypes with RRs in our study supports the probable predictive ability of these genotypes for response to bevacizumabcontaining regimens. Thus far, data regarding the potential association between VEGF genotypes and outcome in colorectal cancer patients receiving bevacizumab-based treatment are extremely limited, and based on studies with relatively small number of patients. 27, 29 Abbreviations: CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; PS, performance status; VEGF, vascular endothelial growth factor.
In conclusion, our results support the potential predictive significance of VEGF genotypes in patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy plus bevacizumab, in terms of RR and OS. However, current results should be validated prospectively, in larger cohorts.
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